AGMB (AgomAb Therapeutics NV) Current Deferred Revenue: $1.45 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

AGMB AgomAb Therapeutics NV AGMB
14 GF Score
Price $14.30
! 1 Warning Sign
View Full Analysis

What is AgomAb Therapeutics NV Current Deferred Revenue?

AgomAb Therapeutics NV AGMB +1.96% 14 Current Deferred Revenue is $1.45 Mil as of Jun. 2026. GuruFocus rates AGMB with a GF Score™ of 14/100. The stock has 1 warning sign investors should review.

Current Deferred Revenue represents collections of cash or other assets related to revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. It can be either current or non-current item. Also called unearned revenue.

AgomAb Therapeutics NV's current deferred revenue for the quarter that ended in Jun. 2026 was $1.45 Mil.

AgomAb Therapeutics NV Current Deferred Revenue Related Terms

AgomAb Therapeutics NV Current Deferred Revenue Historical Data

* Premium members only.

The historical data trend for AgomAb Therapeutics NV's Current Deferred Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

AgomAb Therapeutics NV Current Deferred Revenue Chart

AgomAb Therapeutics NV Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Current Deferred Revenue
0.37 1.88 1.29 0.84 1.71

AgomAb Therapeutics NV Quarterly Data
Dec21 Dec22 Dec23 Dec24 Sep25 Dec25 Jun26
Current Deferred Revenue Get a 7-Day Free Trial 1.29 0.84 1.98 1.71 1.45
AGMB
14GF Score
AgomAb Therapeutics NV AGMB
Current Deferred Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Revenue of $1.45 Mil mean?
AgomAb Therapeutics NV (AGMB) has a Current Deferred Revenue of $1.45 Mil as of Jun. 2026. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on AgomAb Therapeutics NV and its competitors.
Is AgomAb Therapeutics NV's Current Deferred Revenue too high?
AgomAb Therapeutics NV's current Current Deferred Revenue is $1.45 Mil. Overall, AgomAb Therapeutics NV has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does AgomAb Therapeutics NV's Current Deferred Revenue compare to CRMD and RGNX?
AgomAb Therapeutics NV's Current Deferred Revenue of $1.45 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Revenue for a Biotechnology company?
A good Current Deferred Revenue depends on the Biotechnology industry context. However, Current Deferred Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Revenue mean?
A high Current Deferred Revenue can signal that a stock is expensive relative to its fundamentals. Current Deferred Revenue records the total amount of cash received for unfinished services. View historical data on AgomAb Therapeutics NV and its competitors. AgomAb Therapeutics NV's current Current Deferred Revenue is $1.45 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AgomAb Therapeutics NV stock overvalued right now?
AgomAb Therapeutics NV (AGMB) has a current Current Deferred Revenue of $1.45 Mil. The current Current Deferred Revenue is $1.45 Mil. AgomAb Therapeutics NV's overall GF Score™ is 14/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Revenue calculated?
Current Deferred Revenue is calculated from a company's financial statements. For AgomAb Therapeutics NV (AGMB), the current Current Deferred Revenue is $1.45 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

AgomAb Therapeutics NV Business Description

Address 1/6 Posthoflei, Antwerp, BEL, 2600
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.
14GF Score

Get the complete analysis for AGMB

Current Deferred Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$14.30
Price